Omnicell, Inc. (OMCL) Expected to Post Earnings of $0.52 Per Share
Equities analysts predict that Omnicell, Inc. (NASDAQ:OMCL) will announce earnings of $0.52 per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Omnicell’s earnings, with the highest EPS estimate coming in at $0.53 and the lowest estimate coming in at $0.52. Omnicell reported earnings of $0.37 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 40.5%. The business is scheduled to issue its next quarterly earnings results on Wednesday, February 21st.
According to Zacks, analysts expect that Omnicell will report full year earnings of $1.31 per share for the current year, with EPS estimates ranging from $1.30 to $1.32. For the next year, analysts expect that the firm will report earnings of $1.96 per share, with EPS estimates ranging from $1.88 to $2.05. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Omnicell.
Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, October 26th. The company reported $0.42 EPS for the quarter, meeting analysts’ consensus estimates of $0.42. Omnicell had a negative return on equity of 0.79% and a negative net margin of 0.51%. The company had revenue of $186.78 million during the quarter, compared to the consensus estimate of $192.45 million. During the same quarter in the prior year, the firm earned $0.40 EPS. The company’s quarterly revenue was up 5.7% compared to the same quarter last year.
Several brokerages have issued reports on OMCL. Dougherty & Co boosted their target price on shares of Omnicell from $45.00 to $49.00 and gave the company a “buy” rating in a research note on Friday, July 28th. Craig Hallum boosted their target price on shares of Omnicell from $46.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, July 28th. BidaskClub downgraded shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Cantor Fitzgerald reissued a “buy” rating and set a $47.00 target price on shares of Omnicell in a research note on Tuesday, July 25th. Finally, Piper Jaffray Companies reissued a “hold” rating and set a $40.00 target price on shares of Omnicell in a research note on Sunday, July 30th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $54.86.
Shares of Omnicell (OMCL) opened at $46.15 on Tuesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.53 and a quick ratio of 1.08. Omnicell has a one year low of $31.50 and a one year high of $55.40.
In other news, VP Jorge R. Taborga sold 6,295 shares of the company’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $48.69, for a total value of $306,503.55. Following the transaction, the vice president now directly owns 50,013 shares of the company’s stock, valued at $2,435,132.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Dan S. Johnston sold 16,400 shares of the company’s stock in a transaction on Friday, August 18th. The stock was sold at an average price of $48.86, for a total transaction of $801,304.00. Following the completion of the transaction, the executive vice president now directly owns 51,621 shares in the company, valued at $2,522,202.06. The disclosure for this sale can be found here. Insiders sold 47,632 shares of company stock worth $2,370,955 over the last ninety days. 3.77% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its stake in shares of Omnicell by 2.3% in the second quarter. BlackRock Inc. now owns 4,589,119 shares of the company’s stock worth $197,790,000 after acquiring an additional 101,776 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Omnicell by 3.7% in the second quarter. Vanguard Group Inc. now owns 1,928,201 shares of the company’s stock worth $83,105,000 after acquiring an additional 67,902 shares during the last quarter. Conestoga Capital Advisors LLC increased its stake in shares of Omnicell by 0.7% in the third quarter. Conestoga Capital Advisors LLC now owns 1,617,706 shares of the company’s stock worth $82,584,000 after acquiring an additional 11,105 shares during the last quarter. Oak Ridge Investments LLC increased its stake in shares of Omnicell by 0.6% in the second quarter. Oak Ridge Investments LLC now owns 1,537,940 shares of the company’s stock worth $66,285,000 after acquiring an additional 8,491 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in shares of Omnicell by 129.6% in the second quarter. Janus Henderson Group PLC now owns 1,231,933 shares of the company’s stock worth $53,096,000 after acquiring an additional 695,334 shares during the last quarter. 98.64% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/omnicell-inc-omcl-expected-to-post-earnings-of-0-52-per-share/1702305.html.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.